Amicus Therapeutics (FOLD) Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for FOLD from our risk checks.
FOLD Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.43 |
| 52 Week High | US$14.43 |
| 52 Week Low | US$5.51 |
| Beta | 0.49 |
| 1 Month Change | 0.63% |
| 3 Month Change | 1.55% |
| 1 Year Change | 66.05% |
| 3 Year Change | 30.23% |
| 5 Year Change | 56.85% |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Amicus Therapeutics: Moving Towards Consistent Profitability
Nov 11There's No Escaping Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Muted Revenues Despite A 26% Share Price Rise
Aug 24
Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment?
Jul 31
Dimerix Collaboration Will Open Opportunities In US And Europe
Strategic partnerships, robust product launches, and market diversification are key drivers of expected future revenue growth for Amicus Therapeutics.Amicus Therapeutics, Inc. (NASDAQ:FOLD) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 11Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment?
Mar 27Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)
Mar 17Investors Aren't Buying Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Dec 30Amicus Therapeutics: Cheap Heading Into 2025
Dec 27Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden
Nov 10Amicus: Teva Settlement Clears Revenue Path Forward For Galafold
Oct 18'Boring' Amicus Therapeutics Is Making Progress
Sep 29Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Aug 16Little Excitement Around Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues
Jul 02Here's Why Amicus Therapeutics (NASDAQ:FOLD) Can Afford Some Debt
Jun 06Amicus Therapeutics: Too Cheap At Under $10 A Share
May 20Amicus Therapeutics, Inc. (NASDAQ:FOLD) Looks Inexpensive But Perhaps Not Attractive Enough
Mar 27Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
Feb 29Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Could Signal Some Risk
Dec 19Amicus Therapeutics (NASDAQ:FOLD) Is Carrying A Fair Bit Of Debt
Jul 06Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Revenues Are Not Doing Enough For Some Investors
May 14Does Amicus Therapeutics (NASDAQ:FOLD) Have A Healthy Balance Sheet?
Mar 23Shareholder Returns
| FOLD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -3.2% | -2.6% |
| 1Y | 66.1% | 20.8% | 13.1% |
Return vs Industry: FOLD exceeded the US Biotechs industry which returned 20.8% over the past year.
Return vs Market: FOLD exceeded the US Market which returned 13.1% over the past year.
Price Volatility
| FOLD volatility | |
|---|---|
| FOLD Average Weekly Movement | 0.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FOLD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: FOLD's weekly volatility has decreased from 7% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 511 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications.
Amicus Therapeutics, Inc. Fundamentals Summary
| FOLD fundamental statistics | |
|---|---|
| Market cap | US$4.53b |
| Earnings (TTM) | -US$27.11m |
| Revenue (TTM) | US$634.21m |
Is FOLD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FOLD income statement (TTM) | |
|---|---|
| Revenue | US$634.21m |
| Cost of Revenue | US$72.93m |
| Gross Profit | US$561.28m |
| Other Expenses | US$588.39m |
| Earnings | -US$27.11m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.086 |
| Gross Margin | 88.50% |
| Net Profit Margin | -4.27% |
| Debt/Equity Ratio | 143.2% |
How did FOLD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/23 03:37 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amicus Therapeutics, Inc. is covered by 27 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Eade | Argus Research Company |
| Michael Ulz | Baird |
| Yun Zhong | Berenberg |